Literature DB >> 10845917

Increased apoptosis of peripheral blood T cells following allogeneic hematopoietic cell transplantation.

M T Lin1, L H Tseng, H Frangoul, T Gooley, J Pei, A Barsoukov, Y Akatsuka, J A Hansen.   

Abstract

Lymphopenia and immune deficiency are significant problems following allogeneic hematopoietic cell transplantation (HCT). It is largely assumed that delayed immune reconstruction is due to a profound decrease in thymus-dependent lymphopoiesis, especially in older patients, but apoptosis is also known to play a significant role in lymphocyte homeostasis. Peripheral T cells from patients who received HCT were studied for evidence of increased cell death. Spontaneous apoptosis was measured in CD3(+) T cells following a 24-hour incubation using 7-amino-actinomycin D in conjunction with the dual staining of cell surface antigens. Apoptosis was significantly greater among CD3(+) T cells taken from patients 19-23 days after transplantation (30.4% +/- 12.5%, P <.05), and 1 year after transplantation (9.7% +/- 2.8%, P <.05) compared with healthy controls (4.0% +/- 1.5%). Increased apoptosis occurred preferentially in HLA (human leukocyte antigen)-DR positive cells and in both CD3(+)/CD4(+) and CD3(+)/CD8(+) T-cell subsets, while CD56(+)/CD3(-) natural killer cells were relatively resistant to apoptosis. The extent of CD4(+) T-cell apoptosis was greater in patients with grade II-IV acute graft-versus-host disease (GVHD) (33. 9% +/- 11.3%) compared with grade 0-I GVHD (14.6 +/- 6.5%, P <.05). T-cell apoptosis was also greater in patients who received transplantations from HLA-mismatched donors (39.5% +/- 10.4%, P <. 05) or HLA-matched unrelated donors (32.1% +/- 11.4%, P <.05) compared with patients who received transplantations from HLA-identical siblings (19.6% +/- 6.7%). The intensity of apoptosis among CD4(+) T cells was significantly correlated with a lower CD4(+) T-cell count. Together, these observations suggest that activation of T cells in vivo, presumably by alloantigens, predisposes the cells to spontaneous apoptosis, and this phenomenon is associated with lymphopenia. Activation-induced T-cell apoptosis may contribute to delayed immune reconstitution following HCT. (Blood. 2000;95:3832-3839)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10845917

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

1.  Thymic re-entry of mature activated T cells and increased negative selection in vascularized allograft recipients.

Authors:  L A Chau; S Rohekar; J-J Wang; D Lian; S Chakrabarti; L Zhang; R Zhong; J Madrenas
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

2.  IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation.

Authors:  Onder Alpdogan; Stephanie J Muriglan; Jeffrey M Eng; Lucy M Willis; Andrew S Greenberg; Barry J Kappel; Marcel R M van den Brink
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

3.  Age-dependent incidence, time course, and consequences of thymic renewal in adults.

Authors:  Frances T Hakim; Sarfraz A Memon; Rosemarie Cepeda; Elizabeth C Jones; Catherine K Chow; Claude Kasten-Sportes; Jeanne Odom; Barbara A Vance; Barbara L Christensen; Crystal L Mackall; Ronald E Gress
Journal:  J Clin Invest       Date:  2005-03-17       Impact factor: 14.808

4.  Expression of CD27 on peripheral CD4+ T-lymphocytes correlates with the development of severe acute graft-versus-host disease after allogeneic bone marrow transplantation.

Authors:  Hitoshi Yoshida; Tetsuo Maeda; Jun Ishikawa; Shinya Inoue; Hitomi Matsunaga; Satoru Kosugi; Masamichi Shiraga; Kenji Oritani; Yuzuru Kanakura; Yoshiaki Tomiyama
Journal:  Int J Hematol       Date:  2006-11       Impact factor: 2.490

5.  Rapidly proliferating CD44hi peripheral T cells undergo apoptosis and delay posttransplantation T-cell reconstitution after allogeneic bone marrow transplantation.

Authors:  S Onder Alpdogan; Sydney X Lu; Neel Patel; Suzanne McGoldrick; David Suh; Tulin Budak-Alpdogan; Odette M Smith; Jeremy Grubin; Christopher King; Gabrielle L Goldberg; Vanessa M Hubbard; Adam A Kochman; Marcel R M van den Brink
Journal:  Blood       Date:  2008-09-24       Impact factor: 22.113

Review 6.  Thymic T-cell development in allogeneic stem cell transplantation.

Authors:  Werner Krenger; Bruce R Blazar; Georg A Holländer
Journal:  Blood       Date:  2011-03-22       Impact factor: 22.113

7.  Graft-versus-host disease impairs vaccine responses through decreased CD4+ and CD8+ T cell proliferation and increased perforin-mediated CD8+ T cell apoptosis.

Authors:  Christian M Capitini; Nicole M Nasholm; Brynn B Duncan; Martin Guimond; Terry J Fry
Journal:  J Immunol       Date:  2012-12-28       Impact factor: 5.422

8.  GVHD after haploidentical transplantation: a novel, MHC-defined rhesus macaque model identifies CD28- CD8+ T cells as a reservoir of breakthrough T-cell proliferation during costimulation blockade and sirolimus-based immunosuppression.

Authors:  Weston P Miller; Swetha Srinivasan; Angela Panoskaltsis-Mortari; Karnail Singh; Sharon Sen; Kelly Hamby; Taylor Deane; Linda Stempora; Jonathan Beus; Alexa Turner; Caleb Wheeler; Daniel C Anderson; Prachi Sharma; Anapatricia Garcia; Elizabeth Strobert; Eric Elder; Ian Crocker; Timothy Crenshaw; M Cecilia T Penedo; Thea Ward; Mingqing Song; John Horan; Christian P Larsen; Bruce R Blazar; Leslie S Kean
Journal:  Blood       Date:  2010-09-10       Impact factor: 22.113

9.  Emergent autoimmunity in graft-versus-host disease.

Authors:  Elizabeth Tivol; Richard Komorowski; William R Drobyski
Journal:  Blood       Date:  2005-03-03       Impact factor: 22.113

10.  In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity.

Authors:  Ryosei Nishimura; Jeanette Baker; Andreas Beilhack; Robert Zeiser; Janelle A Olson; Emanuela I Sega; Mobin Karimi; Robert S Negrin
Journal:  Blood       Date:  2008-06-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.